About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5296806
Allelic
Composition
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
Genetic
Background
involves: FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ
• neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants
• ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities
• mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development
• rates of mammary epithelial cell proliferation are increased compared to controls
• at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching
• at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts
• 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia
• 52% of mutants at 4 months of age show lobular hyperplasia
• 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias
• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

neoplasm
• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

integument
• exposure to exogenous estrogen does not increase or change the prevalence of ductal abnormalities, proliferative disease or ductal carcinoma in situ
• neither hyperplasia nor ductal carcinoma in situ regress within a 2-week period following doxycycline treatment in 4 month old mutants
• ovariectomized mice do not show ductal hyperplasia, ductal carcinoma in situ or other ductal abnormalities
• mutants which were treated with doxycycline at 3 weeks of age to inhibit Esr1 expression exhibit normal mammary gland development
• rates of mammary epithelial cell proliferation are increased compared to controls
• at 4 months of age, mutants show abnormal mammary ductal structures, including lateral budding, dilated ducts, and abnormal branching
• at 4 months of age, mutants show lateral budding and abnormal branching of mammary gland ducts
• 33% and 36% of mutants at 2 and 4 months of age, respectively, show ductal hyperplasia
• 52% of mutants at 4 months of age show lobular hyperplasia
• 12 month old mice display hyperplastic alveolar nodules with increased frequency of mitotic figures within the hyperplasias
• 17% and 21% of mutants at 2 and 4 months of age, respectively, develop ductal carcinoma in situ

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
breast cancer DOID:1612 OMIM:114480
J:96383


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
10/29/2024
MGI 6.24
The Jackson Laboratory